Three ways Scottish HTA reforms could benefit pharma

Scotland recently announced significant changes to the way it assesses medicines for availability on the NHS, which could benefit pharma companies looking for access in this small but influential market. Among the reforms, Scotland's health technology appraisal body the Scottish Medicines Consortium (SMC) plans to give patients and clinicians a stronger voice in assessments, and to give companies the opportunity to submit patient access schemes to make their drugs more affordable.